梅毒検査の世界市場：2023～2030年

世界の梅毒検査市場は、予測期間中（2023～2030年）にCAGR 6.2％で成長すると予測されています。トレポネーマ・パラジウムは性感染症梅毒を引き起こす細菌です。最初の2段階では、最も感染力が強いです。梅毒の初期段階は潜伏期で、患者に害はないです。症状はないが、この病気はまだ生命力があります。第三梅毒と呼ばれる第二段階は、健康にとって最も有害です。市場を加速させる主な原動力には、性感染症（STD）の有病率の上昇、流産の増加、ヘルスケア業界における効率的な疾病診断・検査ソリューションに対する需要の高まりなどがあります。その結果、市場参入企業は梅毒検査製品やそれに付随するサービスポートフォリオを作成する際に技術開発に注力しており、市場拡大をさらに後押しすることになります。例えば、2023年2月、大学キャンパスにおけるSTIの増加に対抗するため、CarawayとAsh Wellnessは提携を開始しました。クラミジア、淋病、梅毒、HIV、C型肝炎、トリコモナス、カンジダ症、細菌性膣炎などの性感染症（STI）の検査がキットに含まれています。

セグメント別の展望

検査室検査サブセグメントが世界の梅毒検査市場でかなりのシェアを占めると予測される

検査場所のうち、ラボ検査サブセグメントが世界の梅毒検査市場でかなりのシェアを占めると予想されます。このセグメントの成長は、いくつかの血清学的検査、迅速血漿再凝集（RPR）検査、トレポネーマ・パリダム粒子凝集（TPPA）検査の影響力が高まっていること、検査室検査技術の進歩と自動化システムの利用可能性により梅毒検査の効率と納期が改善されたことに起因しています。ヘルスケアキャンペーン、教育プログラム、政府や医療機関によるイニシアチブは、梅毒検査の重要性を強調しています。米国国立衛生研究所（NIH）によると、活動性の梅毒では通常、非トレポネーマル検査が陽性となり、滴定が行われます。フォローアップの血清学的検査でVDRLまたはRPRが陽性となった場合、梅毒が活動中であることを示し、治療効果を追跡するために使用されます。例えば、2023年2月、母子保健企業のMaternova社は、HIV、肝炎、梅毒などのSTI疾患の迅速診断検査を開発・製造し、カナダのノバスコシア州に本社を置くMedMira社と販売提携を結んだ。

地域別展望

世界の梅毒検査市場は、北米（米国、カナダ）、欧州（英国、イタリア、スペイン、ドイツ、フランス、その他欧州地域）、アジア太平洋地域（インド、中国、日本、韓国、その他アジア地域）、世界のその他の地域（中東とアフリカ、ラテンアメリカ）を含む地域別にさらに細分化されています。なかでもアジア太平洋地域は、効率的な医療インフラの整備が進み、ヘルスケア産業が継続的に成長していることから、世界市場で大きなシェアを占めると予想されています。

北米地域は世界の梅毒検査市場において著しいCAGRで成長すると予測される

すべての地域の中で、北米は予測期間中にかなりのCAGRで成長すると予測されています。北米、特に米国は今後も無視できない重要な役割を果たすであろう。同地域の成長は、最新技術の普及と同地域に主要な競合企業が存在することに起因しており、市場プレイヤーにいくつかの拡大機会を提供しています。例えば、2023年3月、HIVと梅毒の二重迅速検査が、2年間の臨床試験でHIV感染の検出精度が100％、活動性梅毒の検出精度が98％であることが明らかにされ、最近カナダ保健省により承認されました。性感染症の迅速検査は、DPP HIV-梅毒システムによってエキサイティングに進歩しました。DPP HIV-梅毒システムは現在、米国内の20万以上のCLIA認定ポイントオブケア検査施設で利用可能です。市場成長を後押しするもう1つの要因は、MSM（男性と性交渉を持つ男性）の症例が増加していることと、妊婦の必須要件としてスクリーニング検査が実施されていることです。

目次

第1章 レポート概要

• 業界の現状分析と成長ポテンシャルの展望
• 調査方法とツール
• 市場内訳
  • セグメント別
  • 地域別

第2章 市場概要と洞察

• 調査範囲
• アナリストの洞察と現在の市場動向
  • 主な調査結果
  • 推奨事項
  • 結論

第3章 競合情勢

• 主要企業分析
• Abbott Laboratories
  • 概要
  • 財務分析
  • SWOT分析
  • 最近の動向
• Becton Dickinson and Co.
  • 会社概要
  • 財務分析
  • SWOT分析
  • 最近の動向
• Bio-Rad Laboratories Inc.
  • 概要
  • 財務分析
  • SWOT分析
  • 最近の動向
• 主要戦略分析

第4章 市場セグメンテーション

• 梅毒検査の世界市場：タイプ別
  • 一次および二次梅毒
  • 潜伏梅毒と三次梅毒
• 梅毒検査の世界市場：検査場所別
  • ラボ検査
  • ポイントオブケア（POC）検査
• 梅毒検査の世界市場：技術別
  • 臨床検査改善法（CLIA）
  • 酵素結合免疫吸着測定法（ELISA）
  • 核酸増幅検査（NAAT）
  • その他
• 梅毒検査の世界市場：エンドユーザー別
  • 病院
  • 診断検査
  • ホームケア

第5章 地域分析

• 北米
  • 米国
  • カナダ
• 欧州
  • 英国
  • ドイツ
  • イタリア
  • スペイン
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 世界のその他の地域

第6章 企業プロファイル

• Astam Dignostic
• Beckman Coulter
• bioLytical laboratories Inc.
• BioMerieux SA
• Cepheid Inc.
• Danaher corp.
• Diasorin S.P.A
• DRG International Inc.（BioCheck Inc.）
• F. Hoffmann-La Roche AG
• Fujirebio
• Hologoic Inc
• Omega diagnostics Group PLC
• Shenzhen new industries Biomedical Engineering Co., Ltd.
• Siemens Healthineers AG
• Thermo Fisher Scientific Inc.

LIST OF TABLES

• 1. GLOBAL SYPHILIS TESTING MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
• 2. GLOBAL PRIMARY AND SECONDARY SYPHILIS TESTING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 3. GLOBAL LATENT AND TERTIARY SYPHILIS TESTING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 4. GLOBAL SYPHILIS TESTING MARKET RESEARCH AND ANALYSIS BY LOCATION OF TESTING, 2022-2030 ($ MILLION)
• 5. GLOBAL SYPHILIS TESTING IN LABORATORY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 6. GLOBAL SYPHILIS TESTING IN POINT-OF-CARE (POC) MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 7. GLOBAL SYPHILIS TESTING MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
• 8. GLOBAL CLIA-BASED SYPHILIS TESTING MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
• 9. GLOBAL ELISA-BASED SYPHILIS TESTING MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
• 10. GLOBAL NAATS-BASED SYPHILIS TESTING MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
• 11. GLOBAL OTHER TECHNOLOGIES BASED SYPHILIS TESTING MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
• 12. GLOBAL SYPHILIS TESTING MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
• 13. GLOBAL SYPHILIS TESTING IN HOSPITALS MARKET RESEARCH AND ANALYSIS 2022-2030 ($ MILLION)
• 14. GLOBAL SYPHILIS TESTING IN DIAGNOSTIC LABS MARKET RESEARCH AND ANALYSIS 2022-2030 ($ MILLION)
• 15. GLOBAL SYPHILIS TESTING IN HOME-CARE MARKET RESEARCH AND ANALYSIS 2022-2030 ($ MILLION)
• 16. GLOBAL SYPHILIS TESTING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 17. NORTH AMERICAN SYPHILIS TESTING MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
• 18. NORTH AMERICAN SYPHILIS TESTING MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
• 19. NORTH AMERICAN SYPHILIS TESTING MARKET RESEARCH AND ANALYSIS BY LOCATION OF TESTING, 2022-2030 ($ MILLION)
• 20. NORTH AMERICAN SYPHILIS TESTING MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
• 21. NORTH AMERICAN SYPHILIS TESTING MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
• 22. NORTH AMERICAN SYPHILIS TESTING MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
• 23. EUROPE SYPHILIS TESTING MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
• 24. EUROPE SYPHILIS TESTING MARKET RESEARCH AND ANALYSIS BY LOCATION OF TESTING, 2022-2030 ($ MILLION)
• 25. EUROPE SYPHILIS TESTING MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
• 26. EUROPE SYPHILIS TESTING MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
• 27. ASIA-PACIFIC SYPHILIS TESTING MARKET RESEARCH AND ANALYSIS BY TYPE 2022-2030 ($ MILLION)
• 28. ASIA-PACIFIC SYPHILIS TESTING MARKET RESEARCH AND ANALYSIS BY LOCATION OF TESTING, 2022-2030 ($ MILLION)
• 29. ASIA-PACIFIC SYPHILIS TESTING MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
• 30. ASIA-PACIFIC SYPHILIS TESTING MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
• 31. REST OF THE WORLD SYPHILIS TESTING MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
• 32. REST OF THE WORLD SYPHILIS TESTING MARKET RESEARCH AND ANALYSIS BY LOCATION OF TESTING, 2022-2030 ($ MILLION)
• 33. REST OF THE WORLD SYPHILIS TESTING MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
• 34. REST OF THE WORLD SYPHILIS TESTING MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)

LIST OF FIGURES

• 1. GLOBAL SYPHILIS TESTING MARKET SHARE BY TYPE, 2022 VS 2030 (%)
• 2. GLOBAL PRIMARY AND SECONDARY SYPHILIS TESTING MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 3. GLOBAL LATENT AND TERTIARY SYPHILIS TESTING MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 4. GLOBAL SYPHILIS TESTING MARKET RESEARCH AND ANALYSIS BY LOCATION OF TESTING, 2022 VS 2030 (%)
• 5. GLOBAL SYPHILIS TESTING IN LABORATORY MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
• 6. GLOBAL SYPHILIS TESTING IN POINT-OF-CARE (POC)MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
• 7. GLOBAL SYPHILIS TESTING MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022 VS 2030 (%)
• 8. GLOBAL CLIA-BASED SYPHILIS TESTING MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022 VS 2030 (%)
• 9. GLOBAL ELISA-BASED SYPHILIS TESTING MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022 VS 2030 (%)
• 10. GLOBAL NAATS-BASED SYPHILIS TESTING MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022 VS 2030 (%)
• 11. GLOBAL OTHER TECHNOLOGIES BASED SYPHILIS TESTING MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022 VS 2030 (%)
• 12. GLOBAL SYPHILIS TESTING MARKET RESEARCH AND ANALYSIS BY END-USER, 2022 VS 2030 (%)
• 13. GLOBAL SYPHILIS TESTING IN HOSPITALS MARKET RESEARCH AND ANALYSIS, 2022 VS 2030 (%)
• 14. GLOBAL SYPHILIS TESTING IN DIAGNOSTIC LABS MARKET RESEARCH AND ANALYSIS, 2022 VS 2030 (%)
• 15. GLOBAL SYPHILIS TESTING IN HOME-CARE MARKET RESEARCH AND ANALYSIS, 2022 VS 2030 (%)
• 16. GLOBAL SYPHILIS TESTING MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
• 17. GLOBAL SYPHILIS TESTING MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 18. US SYPHILIS TESTING MARKET SIZE, 2022-2030 ($ MILLION)
• 19. CANADA SYPHILIS TESTING MARKET SIZE, 2022-2030 ($ MILLION)
• 20. UK SYPHILIS TESTING MARKET SIZE, 2022-2030 ($ MILLION)
• 21. FRANCE SYPHILIS TESTING MARKET SIZE, 2022-2030 ($ MILLION)
• 22. GERMANY SYPHILIS TESTING MARKET SIZE, 2022-2030 ($ MILLION)
• 23. ITALY SYPHILIS TESTING MARKET SIZE, 2022-2030 ($ MILLION)
• 24. SPAIN SYPHILIS TESTING MARKET SIZE, 2022-2030 ($ MILLION)
• 25. REST OF EUROPE SYPHILIS TESTING MARKET SIZE, 2022-2030 ($ MILLION)
• 26. INDIA SYPHILIS TESTING MARKET SIZE, 2022-2030 ($ MILLION)
• 27. CHINA SYPHILIS TESTING MARKET SIZE, 2022-2030 ($ MILLION)
• 28. JAPAN SYPHILIS TESTING MARKET SIZE, 2022-2030 ($ MILLION)
• 29. SOUTH KOREA SYPHILIS TESTING MARKET SIZE, 2022-2030 ($ MILLION)
• 30. REST OF ASIA-PACIFIC SYPHILIS TESTING MARKET SIZE, 2022-2030 ($ MILLION)
• 31. REST OF THE WORLD SYPHILIS TESTING MARKET SIZE, 2022-2030 ($ MILLION)

Title: Global Syphilis Testing Market Size, Share & Trends Analysis Report by Type (Primary and Secondary Syphilis, Latent and Tertiary Syphilis), by Location of Testing (Laboratory Testing, Point-of-Care (POC) Testing), and by Technology (Clinical Laboratory Improvement Amendments (CLIA), Enzyme-Linked Immunosorbent Assay (ELISA), Nucleic Acid Amplification Test (NAAT), and Others), by End User (Hospitals, Diagnostic Labs, Home Care),Forecast Period (2023-2030).

The global syphilis testing market is anticipated to grow at a CAGR of 6.2% during the forecast period (2023-2030). Treponema palladium is the bacterium that causes the sexually transmitted disease syphilis. During the first two phases, it is most contagious. The initial stage of syphilis is the concealed, or latent, stage, during which the patient is not harmed. Although there are no symptoms, the disease is still vital. The second stage of the disease, referred to as tertiary syphilis, is the most harmful to health. Some main driving factor that accelerating the market include the rising prevalence of sexually transmitted infections (STDs), the rise in miscarriages, and the rising demand for efficient disease diagnostic and testing solutions in the healthcare industry. As a result, market participants are concentrating on technology developments when creating syphilis testing products and accompanying service portfolios, which will further support market expansion. For Instance, In February 2023, to combat the rise of STIs on college campuses, Caraway and Ash Wellness started a partnership. tests for STIs and sexually transmitted infections (STIs), such as chlamydia, gonorrhea, syphilis, HIV, hepatitis C, trichomoniasis, candidiasis, and bacterial vaginosis, are included in the kits.

Segmental Outlook

The global syphilis testing market is segmented on the type, location of testing, technology, and end-users. Based on the type, the market is sub-segmented into primary & secondary syphilis and latent & tertiary syphilis. Based on the location of testing, the market is sub-segmented laboratory testing and point-of-care (POC) testing. Further, on the basis of technology, the market is sub-segmented into CLIA, ELISA, NAATs, and others. By end-user, the market is sub-segmented into hospitals, diagnostic labs, and home care.

The Laboratory Testing Sub-Segment is Anticipated to Hold a Considerable Share of the Global Syphilis Testing Market

Among the location of testing, the laboratory testing sub-segment is expected to hold a considerable share of the global syphilis testing market. The segmental growth is attributed to the growing influence of several serological tests, rapid plasma regain (RPR) test, and Treponema pallidum particle agglutination (TPPA) test, and advancements in laboratory testing technologies and the availability of automated systems have improved the efficiency and turnaround time of syphilis testing. Healthcare campaigns, educational programs, and initiatives by governments and healthcare organizations have emphasized the significance of syphilis testing. According to the National Institute of Health (NIH), The nontreponemal test will typically be positive in situations of active syphilis, and a titter will be carried out. When a follow-up serologic test reveals a positive titter with a VDRL or RPR, it indicates that syphilis is active, and it is used to track treatment effectiveness. For instance, in February 2023, the maternal and child health company Maternova established a distribution partnership with MedMira, a creator and manufacturer of quick diagnostic tests for STIs diseases like HIV, hepatitis, syphilis, and others with headquarters in Nova Scotia, Canada.

Regional Outlook

The global syphilis testing market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America. Among these, the Asia-Pacific region is anticipated to hold a prominent share of the market across the globe, owing to the continuously growing healthcare industry coupled with rise in establishment of efficient healthcare infrastructure.

The North America Region is Expected to Grow at a Significant CAGR in the Global Syphilis Testing Market

Among all regions, North America is anticipated to grow at a considerable CAGR over the forecast period. North America, and particularly the US, will continue to play a crucial role that cannot be disregarded. The regional growth is attributed to the widespread use of modern technologies and the presence of major competitors in the region, which offers several opportunities of expansion for market players. For instance, in March 2023, a dual HIV-syphilis fast test was recently approved by Health Canada after a two-year clinical trial revealed that it was 100% accurate at detecting HIV infections and 98% accurate in detecting active syphilis. Rapid testing for sexually transmitted illnesses has excitingly advanced with the DPP HIV-Syphilis System. The DPP HIV-Syphilis System is currently available to more than 200,000 CLIA-waived point-of-care testing facilities in the US. Another factor bolstering the market growth is owing to the rising MSM (men having sex with men) cases along with the implementation of screening tests as a requirement for pregnant women.

Market Players Outlook

The major companies serving the syphilis testing market include: Abbott laboratories, Bio-Rad laboratories Inc., F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Hologoic Inc. and others. By using a variety of techniques, including as mergers and acquisitions, partnerships, collaborations, funding, and the launch of new products, companies in the industry are significantly boosting market growth. For instance, in March 2023 Health Canada grants authorization to bioLytical laboratories Inc. for its INSTI® Multiplex HIV-1/2 syphilis antibody test. The test lessens test anxiety for patients by enabling medical practitioners to test more people in less time by providing results for two infections with just one sample.

The Report Covers:

• Market value data analysis of 2022 and forecast to 2030.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global syphilis testing market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

• Current Industry Analysis and Growth Potential Outlook
• 1.1. Research Methods and Tools
• 1.2. Market Breakdown
  • 1.2.1. By Segments
  • 1.2.2. By Region

2. Market Overview and Insights

• 2.1. Scope of the Report
• 2.2. Analyst Insight & Current Market Trends
  • 2.2.1. Key Findings
  • 2.2.2. Recommendations
  • 2.2.3. Conclusion

3. Competitive Landscape

• 3.1. Key Company Analysis
• 3.2. Abbott Laboratories
  • 3.2.1. Overview
  • 3.2.2. Financial Analysis
  • 3.2.3. SWOT Analysis
  • 3.2.4. Recent Developments
• 3.3. Becton Dickinson and Co.
  • 3.3.1. Overview
  • 3.3.2. Financial Analysis
  • 3.3.3. SWOT Analysis
  • 3.3.4. Recent Developments
• 3.4. Bio-Rad Laboratories Inc.
  • 3.4.1. Overview
  • 3.4.2. Financial Analysis
  • 3.4.3. SWOT Analysis
  • 3.4.4. Recent Developments
• 3.5. Key Strategy Analysis

4. Market Segmentation

• 4.1. Global Syphilis Testing Market by Type
  • 4.1.1. Primary and secondary Syphilis
  • 4.1.2. Latent and Tertiary Syphilis
• 4.2. Global Syphilis Testing Market by Location of Testing
  • 4.2.1. Laboratory Testing
  • 4.2.2. Point-of-Care (POC) Testing
• 4.3. Global Syphilis Testing Market by Technology
  • 4.3.1. Clinical Laboratory Improvement Amendments (CLIA)
  • 4.3.2. Enzyme-Linked Immunosorbent Assay (ELISA)
  • 4.3.3. Nucleic Acid Amplification Test (NAAT)
  • 4.3.4. Others
• 4.4. Global Syphilis Testing Market by End User
  • 4.4.1. Hospitals
  • 4.4.2. Diagnostic Test
  • 4.4.3. Home Care

5. Regional Analysis

• 5.1. North America
  • 5.1.1. United States
  • 5.1.2. Canada
• 5.2. Europe
  • 5.2.1. UK
  • 5.2.2. Germany
  • 5.2.3. Italy
  • 5.2.4. Spain
  • 5.2.5. France
  • 5.2.6. Rest of Europe
• 5.3. Asia-Pacific
  • 5.3.1. China
  • 5.3.2. India
  • 5.3.3. Japan
  • 5.3.4. South Korea
  • 5.3.5. Rest of Asia-Pacific
• 5.4. Rest of the World

6. Company Profiles

• 6.1. Astam Dignostic
• 6.2. Beckman Coulter
• 6.3. bioLytical laboratories Inc.
• 6.4. BioMerieux SA
• 6.5. Cepheid Inc.
• 6.6. Danaher corp.
• 6.7. Diasorin S.P.A
• 6.8. DRG International Inc. (BioCheck Inc.)
• 6.9. F. Hoffmann-La Roche AG
• 6.10. Fujirebio
• 6.11. Hologoic Inc
• 6.12. Omega diagnostics Group PLC
• 6.13. Shenzhen new industries Biomedical Engineering Co., Ltd.
• 6.14. Siemens Healthineers AG
• 6.15. Thermo Fisher Scientific Inc.